{
  "videos": {
    "gi-cancer-asco-2024-practice-changing": {
      "source": "asco",
      "title": "GI Cancer ASCO 2024 Practice Changing",
      "url": "https://www.asco.org/meetings-education/asco-annual-meeting/abstracts/gi-cancer-asco-2024-practice-changing",
      "video": "https://www.asco.org/videos/gi-cancer-asco-2024-practice-changing",
      "youtube": "bhVDYM0U-5E",
      "transcript": "videos/gi-cancer.json"
    },
    "asco-2024-and-esmo-gi-2024": {
      "source": "asco-esmo",
      "title": "ASCO-ESMO GI 2024",
      "url": "https://www.asco.org/meetings-education/asco-annual-meeting/abstracts/asco-esmo-gi-2024",
      "video": "https://www.asco.org/videos/asco-esmo-gi-2024",
      "youtube": "wfOO5BXBrhc",
      "transcript": "videos/asco-2024-and-esmo-gi-2024.json"
    },
    "ucsf-bay-area-breast-cancer": {
      "source": "ucsf",
      "title": "UCSF Bay Area Breast Cancer",
      "url": "https://www.ucsf.edu/news/2023/09/ucsf-bay-area-breast-cancer",
      "video": "https://www.ucsf.edu/video/ucsf-bay-area-breast-cancer",
      "youtube": "JyYo6Z2cWrk",
      "transcript": "videos/ucsf-bay-area-breast-cancer.json"
    }
  },
  "advisors": {
    "rachel-green": {
      "img": "img/jane-doe.webp",
      "name": "Rachel Green",
      "role": "Senior Manager, Brand/Product Strategy",
      "age": 38,
      "background": "MBA in Marketing, 12 years in the pharmaceutical industry, focusing on oncology.",
      "specialties": "Market positioning, brand lifecycle management, cross-functional collaboration.",
      "clientele": "Healthcare professionals, advocacy groups, and patient networks.",
      "goals": "Identify market opportunities and create impactful strategies for oncology products.",
      "challenges": "Addressing competition, staying updated with clinical advancements, and tailoring brand messages.",
      "interests": "New treatment options, emerging clinical data, market differentiation, patient advocacy insights, competitive landscape analysis, treatment access strategies.",
      "highlights": {
        "gi-cancer-asco-2024-practice-changing": [
          {
            "p": "<strong>S-EPEC Plenary Strategic Impact</strong>: Your MBA analytical skills are vital in understanding why this study at 2:10 earned plenary status at ASCO 2024. As one of only five featured studies, its focus on comparing community versus academic treatment approaches directly informs your market segmentation and access strategies.",
            "start_time": 130.88
          },
          {
            "p": "<strong>CROSS to FLOT Evolution Analysis</strong>: Drawing on your pharmaceutical expertise, the discussion at 2:38 of CROSS's evolution from breakthrough to control arm demonstrates the dynamic nature of treatment standards, crucial for your product lifecycle planning and market positioning.",
            "start_time": 158.42
          },
          {
            "p": "<strong>Treatment Protocol Implementation</strong>: Your market strategy role benefits from the analysis at 3:39 of how methodological challenges in evolving treatment landscapes impact protocol adoption, informing your educational initiatives and stakeholder engagement.",
            "start_time": 219.12
          },
          {
            "p": "<strong>Market Access Pattern Analysis</strong>: Leveraging your expertise in market segmentation, the discussion at 6:41 about different implementation approaches between academic and community settings provides crucial insights for developing targeted access strategies.",
            "start_time": 401.94
          },
          {
            "p": "<strong>Treatment Sequencing Strategy</strong>: Your brand strategy background enhances the interpretation at 8:20 of optimal treatment sequencing data, crucial for developing comprehensive market access and educational programs.",
            "start_time": 500.68
          },
          {
            "p": "<strong>Cross-disciplinary Integration</strong>: Your strategic planning expertise aligns with the emphasis at 9:54 on multidisciplinary care coordination, informing your approach to facilitating collaborative treatment decision-making.",
            "start_time": 594.18
          },
          {
            "p": "<strong>Clinical Practice Evolution</strong>: Your MBA analytical skills are valuable in assessing the discussion at 11:27 about rapidly changing treatment standards and their impact on clinical practice patterns, crucial for market adaptation strategies.",
            "start_time": 687.94
          },
          {
            "p": "<strong>Patient Outcome Optimization</strong>: Your pharmaceutical background enriches the analysis at 13:51 of treatment outcomes and safety profiles, supporting your development of targeted educational and market access initiatives.",
            "start_time": 831.21
          },
          {
            "p": "<strong>Market Implementation Framework</strong>: Your strategic role benefits from the insights at 16:06 about implementing complex treatment protocols across different practice settings, informing your comprehensive market access planning.",
            "start_time": 966.21
          },
          {
            "p": "<strong>Future Treatment Integration</strong>: Drawing on your brand strategy expertise, the discussion at 18:58 about emerging treatment approaches and their integration into current protocols guides your long-term market planning strategies.",
            "start_time": 1138.21
          }
        ],
        "asco-2024-and-esmo-gi-2024": [
          {
            "p": "<strong>MGH-Harvard Research Network Impact</strong>: As Senior Manager in Brand/Product Strategy, Dr. Kuntner's leadership in gastric and esophageal cancer genomics at MGH-Harvard, combined with NRG and NCI committee roles, provides crucial insights. This institutional research network aligns with your goal of identifying strategic partnerships and market opportunities.",
            "start_time": 103.44
          },
          {
            "p": "<strong>S-EPEC Trial Market Strategy</strong>: Your pharmaceutical background enhances appreciation of the S-EPEC trial comparing FLOT versus CROSS approaches. The study's focus on real-world treatment patterns between academic and community settings directly informs your market positioning and access strategies.",
            "start_time": 432.18
          },
          {
            "p": "<strong>FLOT Completion Rate Analysis</strong>: Drawing on your MBA analytical skills, the completion rate comparison (90% preoperative vs 50% postoperative FLOT) provides critical market insights. This data supports your specialty in developing evidence-based market access programs and educational initiatives.",
            "start_time": 747.5
          },
          {
            "p": "<strong>INFINITY No-Surgery Trial</strong>: Your interest in patient-centric approaches aligns with INFINITY's investigation of surgery avoidance in select patients. This innovative trial design informs your strategy for positioning treatments that enhance patient quality of life.",
            "start_time": 921.42
          },
          {
            "p": "<strong>RENAISSANCE Stage IV Strategy</strong>: Leveraging your role in brand strategy, the RENAISSANCE trial's examination of surgical timing in stage IV disease provides key market insights. The findings inform your product positioning across different treatment settings and patient segments.",
            "start_time": 1141.32
          },
          {
            "p": "<strong>ARMANI Treatment Optimization</strong>: Your background in market differentiation benefits from ARMANI's focus on treatment sequence optimization. The study's emphasis on maximizing therapeutic benefit aligns with your goal of developing comprehensive market strategies.",
            "start_time": 1308.78
          },
          {
            "p": "<strong>Keynote 585/811 Integration</strong>: Your specialty in strategic planning is enhanced by understanding Keynote 585's stage II/III immunotherapy findings and Keynote 811's HER2-positive results. This data guides your immunotherapy positioning strategies across different disease stages.",
            "start_time": 1549.12
          },
          {
            "p": "<strong>Claudin-18.2 Market Opportunity</strong>: Aligning with your goal of identifying market opportunities, the Spotlight and GLOW trials of zolbetuximab targeting Claudin-18.2 present key strategic insights. The anticipated November FDA approval timeline informs your market preparation and launch planning.",
            "start_time": 1785.36
          },
          {
            "p": "<strong>Novel Targets Pipeline Analysis</strong>: Your pharmaceutical expertise is valuable in analyzing emerging targets (FGFR-2B, TIGIT, MET). This pipeline assessment supports your interest in developing innovative market strategies and identifying future growth opportunities.",
            "start_time": 2108.89
          },
          {
            "p": "<strong>Regional Treatment Strategy</strong>: Drawing on your role in global market strategy, the discussion at 35:26 about regional preferences for treatment regimens (US vs Asia) informs your market access planning and regional adaptation strategies.",
            "start_time": 2126.25
          },
          {
            "p": "<strong>Three-Year Survival Data in Stage IV Disease</strong>: Your MBA analytical background is valuable in interpreting the survival data at 35:43, showing how precise long-term survival metrics (3-year, 4-year outcomes) inform patient communications and market planning strategies.",
            "start_time": 2143.67
          },
          {
            "p": "<strong>Zolbetuximab Plus Chemotherapy Efficacy Analysis</strong>: Drawing on your pharmaceutical expertise, the analysis at 36:23 demonstrates a significant 5% improvement in 3-year survival rates (20% vs 15%) with zolbetuximab addition, providing concrete data for market differentiation.",
            "start_time": 2183.83
          },
          {
            "p": "<strong>Median Survival Benefit Assessment</strong>: Your strategic planning role benefits from the detailed comparison at 36:48 showing three-month median survival improvement, paralleling immune therapy patterns and informing value proposition development.",
            "start_time": 2208.35
          },
          {
            "p": "<strong>Market Positioning Strategy</strong>: Your background in market differentiation is enhanced by the discussion at 37:25 about treatment sequencing and combination therapy approaches. This insight supports your development of comprehensive market strategies.",
            "start_time": 2245.67
          },
          {
            "p": "<strong>Competitive Landscape Analysis</strong>: The analysis at 38:03 of emerging treatment options and their impact on market dynamics informs your competitive positioning strategies. This data supports your goal of identifying market opportunities and creating impactful strategies.",
            "start_time": 2283.83
          },
          {
            "p": "<strong>Treatment Access Strategies</strong>: Your role in strategic planning benefits from the discussion at 38:42 about treatment access and patient advocacy. This insight supports your development of market access strategies and educational initiatives.",
            "start_time": 2322.25
          },
          {
            "p": "<strong>Market Forecasting Insights</strong>: The presentation's data on market trends and growth opportunities informs your market forecasting and strategic planning. This insight supports your goal of identifying market opportunities and creating impactful strategies.",
            "start_time": 2360.67
          },
          {
            "p": "<strong>Brand Lifecycle Management</strong>: Your background in brand lifecycle management is enhanced by the discussion at 40:00 about product positioning and market access strategies. This insight supports your development of comprehensive brand strategies.",
            "start_time": 2400.83
          },
          {
            "p": "<strong>Cross-functional Collaboration</strong>: The emphasis on cross-functional collaboration at 40:40 demonstrates effective team-based approaches. This insight supports your role in facilitating collaborative care discussions and developing comprehensive market strategies.",
            "start_time": 2440.25
          }
        ],
        "ucsf-bay-area-breast-cancer": [
          {
            "p": "<strong>Surgical Expertise</strong>: Rachel demonstrates her surgical expertise by analyzing lymph node procedures in NSABP trials. She leads the endocrine optimization program and provides critical insights into surgical outcomes from clinical trials. Her innovative approach to patient care is evident through her analysis of individualized treatment strategies.",
            "start_time": 54.02
          },
          {
            "p": "<strong>Clinical Research Excellence</strong>: Rachel's research leadership shines through her telemedicine patient outreach initiatives. She analyzes Alliance trial outcomes and evaluates surgical protocol modifications. Her expertise in treatment optimization is demonstrated through comprehensive protocol analysis.",
            "start_time": 174.1
          },
          {
            "p": "<strong>Patient Care Innovation</strong>: Rachel's commitment to patient-centered care is evident when discussing treatment patterns across institutions. She analyzes patient outcomes and focuses on optimizing treatment protocols. Her strategic approach to patient care is highlighted through innovative methodologies.",
            "start_time": 555.5
          },
          {
            "p": "<strong>Treatment Strategy Development</strong>: Rachel showcases her expertise in developing targeted treatment approaches. Her analysis of surgical outcomes informs protocol development, while she demonstrates leadership in implementing evidence-based practices and provides insights into strategic treatment planning.",
            "start_time": 784.78
          },
          {
            "p": "<strong>Complex Case Management</strong>: Rachel expertly analyzes estrogen-positive tumor cases, demonstrating her deep understanding of cancer biology. Her insights into treatment planning showcase her expertise in managing complex cases, and she discusses long-term risk assessment strategies.",
            "start_time": 1082.66
          },
          {
            "p": "<strong>Treatment Protocol Innovation</strong>: Rachel's leadership in protocol development is evident through her comprehensive treatment analysis. She discusses innovative treatment approaches and evaluates treatment efficacy across different patient populations.",
            "start_time": 1247.84
          },
          {
            "p": "<strong>Clinical Decision Making</strong>: Rachel demonstrates her expertise in evidence-based decision making. Her analysis of treatment outcomes informs protocol development, while she provides insights into managing treatment complications.",
            "start_time": 1407.16
          },
          {
            "p": "<strong>Patient-Centered Strategies</strong>: Rachel's commitment to personalized care is shown through her discussion of patient-specific factors. She analyzes treatment adaptations and focuses on optimizing patient outcomes.",
            "start_time": 1548.14
          },
          {
            "p": "<strong>Therapeutic Advancement</strong>: Rachel leads discussions on innovative therapy approaches. Her expertise in treatment optimization is demonstrated through detailed case analyses, and she evaluates protocol implementation strategies.",
            "start_time": 2144.18
          },
          {
            "p": "<strong>Research Leadership</strong>: Rachel's research expertise is evident when discussing treatment adaptations. She analyzes clinical trial outcomes and provides insights into protocol development.",
            "start_time": 2403.28
          },
          {
            "p": "<strong>Clinical Excellence</strong>: Rachel demonstrates her expertise in managing complex cases. Her leadership in treatment planning is shown through innovative approaches to patient care.",
            "start_time": 2529.14
          },
          {
            "p": "<strong>Treatment Innovation</strong>: Rachel's commitment to advancing treatment protocols is evident through her analysis of therapeutic strategies. She evaluates treatment outcomes and focuses on protocol optimization.",
            "start_time": 2709.46
          },
          {
            "p": "<strong>Healthcare Integration</strong>: Rachel analyzes cross-institutional collaboration in cancer care. Her expertise in system optimization is demonstrated through standardized protocol implementation, and she evaluates healthcare delivery strategies.",
            "start_time": 3368.92
          },
          {
            "p": "<strong>Protocol Development</strong>: Rachel's leadership in protocol development is shown through comprehensive treatment analysis. She discusses evidence-based practices and provides insights into treatment standardization.",
            "start_time": 3847.1
          },
          {
            "p": "<strong>Treatment Framework</strong>: Rachel outlines sustainable treatment frameworks. Her expertise in protocol implementation is demonstrated as she analyzes long-term treatment strategies.",
            "start_time": 4007.4
          },
          {
            "p": "<strong>Evidence-Based Practice</strong>: Rachel's commitment to evidence-based care is evident through her analysis of treatment outcomes. She discusses protocol optimization and focuses on advancing cancer care through research-driven approaches.",
            "start_time": 4144.18
          }
        ]
      }
    },
    "david-wilson": {
      "img": "img/michael-brown.webp",
      "name": "David Wilson",
      "role": "Regional MSL, Oncology",
      "age": 45,
      "background": "PharmD, 15 years in medical affairs, with 8 years specializing in gastrointestinal oncology.",
      "specialties": "Stakeholder engagement, KOL (Key Opinion Leader) management, education delivery.",
      "clientele": "Oncologists, surgeons, and research coordinators.",
      "goals": "Build relationships with KOLs, ensure accurate dissemination of medical information, and support clinical education.",
      "challenges": "Translating complex data into actionable insights, maintaining credibility, and addressing tough scientific questions.",
      "interests": "Immunotherapy breakthroughs, chemotherapy advancements, clinical trial data, treatment guidelines, and patient case studies.",
      "highlights": {
        "gi-cancer-asco-2024-practice-changing": [
          {
            "p": "<strong>S-EPEC Plenary Selection Impact</strong>: As an MSL with 15 years in medical affairs, the selection of S-EPEC as one of only five plenary studies provides you with a powerful context for KOL discussions about the evolving esophageal adenocarcinoma treatment landscape.",
            "start_time": 44.64
          },
          {
            "p": "<strong>CROSS Protocol Historical Evolution</strong>: The detailed history of CROSS protocol from 2012 offers valuable historical perspective for your educational initiatives. This background enhances your ability to discuss treatment evolution with healthcare providers.",
            "start_time": 96.82
          },
          {
            "p": "<strong>Community vs Academic Treatment Patterns</strong>: The analysis of chemoradiation prevalence in community settings versus FLOT in academic centers aligns with your role in bridging treatment approaches across different practice settings.",
            "start_time": 119.60
          },
          {
            "p": "<strong>FLOT Trial Completion Analysis</strong>: The data showing 90% completion of preoperative FLOT but only 50% reaching postoperative therapy provides crucial insights for your discussions about treatment sequencing and patient management.",
            "start_time": 202.06
          },
          {
            "p": "<strong>NeoAges Trial Methodological Insights</strong>: The discussion of NeoAges trial's timing during the transition from epiribicin-based treatments to FLOT offers valuable teaching points about clinical trial design evolution.",
            "start_time": 298.26
          },
          {
            "p": "<strong>Checkmate 577 Integration Strategy</strong>: Dr. Goodman's insights about potential synergies between radiation and adjuvant immunotherapy provide key discussion points for your KOL interactions about treatment optimization.",
            "start_time": 350.94
          },
          {
            "p": "<strong>CROSS Protocol Compliance Criteria</strong>: The detailed analysis of CROSS completion criteria, including the impact of missing even a single chemotherapy dose, offers important context for discussions about protocol adherence.",
            "start_time": 455.74
          },
          {
            "p": "<strong>Multidisciplinary Care Implementation</strong>: The emphasis on tumor board involvement and cross-specialty collaboration aligns with your goal of facilitating comprehensive treatment planning discussions.",
            "start_time": 594.18
          },
          {
            "p": "<strong>FLOT4 Long-term Outcomes</strong>: The comparison with historical FLOT4 data provides valuable context for your discussions about long-term treatment outcomes and the evolution of perioperative chemotherapy approaches.",
            "start_time": 687.94
          },
          {
            "p": "<strong>Treatment Selection Criteria</strong>: The analysis of patient factors influencing treatment decisions between CROSS and FLOT approaches offers crucial insights for your educational role in helping clinicians optimize patient selection.",
            "start_time": 831.21
          },
          {
            "p": "<strong>Real-world Implementation Challenges</strong>: The discussion of practical challenges in implementing both CROSS and FLOT protocols provides important teaching points for your interactions with community oncologists.",
            "start_time": 1049.05
          },
          {
            "p": "<strong>Future Trial Design Considerations</strong>: The examination of how evolving standards of care impact ongoing trials offers valuable insights for your discussions about emerging research with investigators and research coordinators.",
            "start_time": 1298.82
          }
        ],
        "asco-2024-and-esmo-gi-2024": [
          {
            "p": "<strong>FLOT vs CROSS Treatment Paradigm</strong>: The shift from chemoradiation to FLOT as the preferred standard of care provides you with critical context for educating healthcare providers about evolving treatment landscapes in esophageal cancer.",
            "start_time": 169.02
          },
          {
            "p": "<strong>Micrometastatic Disease Management</strong>: The discussion of microscopic cancer cells and their role in recurrence offers valuable teaching points for your interactions about the importance of systemic therapy approaches.",
            "start_time": 296.96
          },
          {
            "p": "<strong>INFINITY Trial Insights</strong>: The potential pathway to surgery-free approaches aligns with your role in discussing patient-centric treatment options and emerging clinical trial opportunities.",
            "start_time": 378.76
          },
          {
            "p": "<strong>Renaissance Trial Analysis</strong>: The evidence regarding surgical intervention in stage IV disease provides crucial discussion points for your interactions with multidisciplinary teams about treatment sequencing.",
            "start_time": 488.94
          },
          {
            "p": "<strong>ARMANI Protocol Implementation</strong>: The emphasis on comprehensive treatment utilization offers important context for your discussions about optimizing patient care pathways and resource allocation.",
            "start_time": 544.18
          },
          {
            "p": "<strong>Keynote 585 Trial Updates</strong>: The ongoing evaluation of immunotherapy in stage II/III disease provides key insights for your educational initiatives about evolving treatment paradigms.",
            "start_time": 634.12
          },
          {
            "p": "<strong>Keynote 811 Patient Selection</strong>: The focus on patient selection for HER2-targeted immunotherapy combinations enhances your ability to facilitate discussions about biomarker-driven treatment approaches.",
            "start_time": 747.50
          },
          {
            "p": "<strong>Zolbetuximab Development</strong>: The anticipated FDA approval of zolbetuximab offers valuable context for your discussions about emerging targeted therapies and their integration into treatment algorithms.",
            "start_time": 858.16
          },
          {
            "p": "<strong>Novel Target Exploration</strong>: The examination of FGFR-2B, TIGIT, and MET pathways provides crucial material for your educational sessions about the expanding landscape of precision medicine.",
            "start_time": 978.96
          },
          {
            "p": "<strong>Real-world Evidence Integration</strong>: The presentation of clinical trial populations reflecting real-world patients strengthens your ability to discuss practical implementation of research findings.",
            "start_time": 1082.28
          },
          {
            "p": "<strong>Treatment Completion Analysis</strong>: The data on therapy completion rates across different protocols provides important context for your discussions about treatment adherence and patient support.",
            "start_time": 1211.72
          },
          {
            "p": "<strong>Future Research Directions</strong>: The overview of upcoming clinical trials and therapeutic targets enhances your ability to engage KOLs in discussions about the future of gastric cancer treatment.",
            "start_time": 1352.56
          },
          {
            "p": "<strong>Survival Data Interpretation</strong>: The detailed analysis of survival curves and risk tables provides you with essential statistical context for discussing treatment outcomes with healthcare providers.",
            "start_time": 1391.06
          },
          {
            "p": "<strong>Biomarker-Driven Strategies</strong>: The discussion of patient stratification based on molecular markers enhances your ability to facilitate precision medicine discussions with oncology teams.",
            "start_time": 1446.10
          },
          {
            "p": "<strong>Quality of Life Considerations</strong>: The presentation's emphasis on treatment tolerability and patient experience offers valuable insights for your discussions about holistic patient care approaches.",
            "start_time": 1492.32
          },
          {
            "p": "<strong>Clinical Trial Design Evolution</strong>: The analysis of adaptive trial designs and endpoint selection provides crucial context for your interactions with research teams and investigators.",
            "start_time": 1549.12
          },
          {
            "p": "<strong>Treatment Sequencing Strategies</strong>: The evaluation of optimal treatment sequencing across different patient populations offers important teaching points for your educational initiatives.",
            "start_time": 1604.10
          },
          {
            "p": "<strong>Multidisciplinary Collaboration</strong>: The emphasis on team-based approaches to patient care aligns with your role in facilitating cross-specialty communication and treatment planning.",
            "start_time": 1836.92
          },
          {
            "p": "<strong>Future Research Directions</strong>: The discussion of upcoming trials and therapeutic approaches provides valuable context for your long-term strategic planning with research teams.",
            "start_time": 1944.51
          },
          {
            "p": "<strong>Implementation Challenges</strong>: The analysis of real-world implementation barriers and solutions offers crucial insights for your discussions about treatment protocol adoption.",
            "start_time": 2060.77
          },
          {
            "p": "<strong>Biomarker-Driven Therapy</strong>: The discussion of novel biomarker-driven approaches, particularly in HER2-positive and Claudin-18.2-positive patients, provides valuable insights for educating healthcare providers about precision medicine strategies.",
            "start_time": 2169.39
          },
          {
            "p": "<strong>Clinical Trial Updates</strong>: The presentation of recent clinical trial results, including survival data and response rates, offers critical information for your discussions with healthcare providers about evolving treatment standards.",
            "start_time": 2330.63
          },
          {
            "p": "<strong>Patient Selection Criteria</strong>: The analysis of patient selection strategies for various treatment approaches provides important guidance for your educational efforts about optimizing treatment decisions.",
            "start_time": 2482.31
          },
          {
            "p": "<strong>Safety Profile Analysis</strong>: The detailed discussion of treatment-related adverse events and management strategies enriches your ability to educate healthcare providers about balancing efficacy and safety.",
            "start_time": 2634.59
          },
          {
            "p": "<strong>Future Treatment Directions</strong>: The exploration of emerging therapeutic approaches and ongoing clinical trials provides valuable context for your discussions about the evolving treatment landscape.",
            "start_time": 2791.43
          }
        ],
        "ucsf-bay-area-breast-cancer": [
          {
            "p": "<strong>Clinical Updates from ASCO</strong>: Dr. Hope Rugo presents key clinical trial outcomes from ASCO 2024, providing you with actionable data points for KOL discussions. The presentation highlights significant improvements in progression-free survival and response rates, essential for educating healthcare providers about evolving treatment standards.",
            "start_time": 54.02
          },
          {
            "p": "<strong>Surgical Protocol Advances</strong>: The discussion of surgical techniques by Dr. Alvarado and Dr. Tang offers critical insights for your educational initiatives. Their comparative analysis of outcomes between different surgical approaches provides evidence-based data to support treatment decision discussions with healthcare providers.",
            "start_time": 115.3
          },
          {
            "p": "<strong>Treatment Optimization Data</strong>: Dr. Chen's presentation of endocrine optimization and neoadjuvant treatment outcomes through the ISPI program provides valuable efficacy data for your KOL engagement. The real-world evidence from clinical trials supports your role in bridging research findings with clinical practice.",
            "start_time": 137.92
          },
          {
            "p": "<strong>Digital Health Integration</strong>: Dr. Natsuhara's telemedicine research presents implementation data and patient outcomes that inform your discussions about practice optimization. These findings help you guide healthcare providers in integrating technology-enabled care delivery solutions.",
            "start_time": 218.66
          },
          {
            "p": "<strong>Lymph Node Management Evidence</strong>: The comparative analysis of sentinel lymph node biopsy versus traditional methods provides crucial efficacy and safety data for your educational programs. This evidence-based approach helps you guide clinicians in protocol selection and implementation.",
            "start_time": 1142.86
          },
          {
            "p": "<strong>Precision Medicine Implementation</strong>: The presentation of biomarker-driven treatment selection and outcomes data strengthens your ability to educate providers about personalized therapy approaches. The discussion includes practical guidance for patient stratification and treatment optimization.",
            "start_time": 1357.16
          },
          {
            "p": "<strong>Clinical Trial Outcomes</strong>: The detailed analysis of recent trial results provides you with concrete data points about treatment effectiveness across different patient subgroups. This information enhances your ability to support evidence-based decision-making in clinical practice.",
            "start_time": 1506.36
          },
          {
            "p": "<strong>Patient-Centered Protocol Design</strong>: The presentation of quality-of-life outcomes and shared decision-making approaches offers practical implementation strategies for your healthcare provider education. The data supports discussions about balancing treatment efficacy with patient experience.",
            "start_time": 1763.82
          },
          {
            "p": "<strong>Novel Treatment Integration</strong>: The discussion of emerging therapies and their clinical validation provides key data points for your KOL engagement. The presentation includes practical guidance for incorporating new treatment modalities into existing protocols.",
            "start_time": 2144.18
          },
          {
            "p": "<strong>Multidisciplinary Care Coordination</strong>: The evidence supporting team-based treatment approaches offers valuable insights for your educational initiatives. The outcomes data demonstrates the impact of coordinated care on treatment success rates.",
            "start_time": 2368.08
          },
          {
            "p": "<strong>Research Translation to Practice</strong>: The presentation of ongoing clinical programs provides you with updates on emerging treatment approaches and their practical implementation. This information supports your role in helping clinicians adapt to evolving treatment landscapes.",
            "start_time": 2709.46
          },
          {
            "p": "<strong>Treatment Evolution Data</strong>: The discussion of future developments includes comparative effectiveness data and implementation strategies, essential for your KOL discussions about advancing treatment standards. The evidence supports your educational efforts in preparing healthcare providers for emerging therapeutic options.",
            "start_time": 3368.08
          },
          {
            "p": "<strong>Hormone Therapy Protocol Updates</strong>: The presentation of advanced treatment strategies for hormone receptor-positive breast cancers includes specific response rates and patient selection criteria, strengthening your ability to guide clinical decision-making.",
            "start_time": 3582.44
          },
          {
            "p": "<strong>Clinical Trial Efficacy Data</strong>: The analysis of B40-41 trial outcomes provides concrete survival and response data across different breast cancer subtypes. This evidence enhances your ability to support healthcare providers in optimizing treatment selection.",
            "start_time": 3845.62
          },
          {
            "p": "<strong>Long-term Monitoring Protocols</strong>: The discussion of patient monitoring approaches includes specific follow-up protocols and outcome measures, supporting your educational initiatives about comprehensive cancer care management.",
            "start_time": 4102.28
          },
          {
            "p": "<strong>Clinical Case Management</strong>: The Q&A session addresses practical challenges in patient care, providing you with real-world scenarios and evidence-based solutions to share during healthcare provider education sessions.",
            "start_time": 4256.14
          }
        ]
      }
    },
    "emily-harper": {
      "img": "img/emily-turner.webp",
      "name": "Emily Harper",
      "role": "Manager, Medical Scientific Communications",
      "age": 33,
      "background": "MSc in Scientific Writing, 8 years of experience in oncology publications and educational materials.",
      "specialties": "Publication planning, scientific messaging, and cross-team collaboration.",
      "clientele": "Internal stakeholders (medical affairs, R&D) and external audiences (HCPs, journals).",
      "goals": "Develop clear, accurate, and impactful scientific content aligned with regulatory standards.",
      "challenges": "Managing timelines, ensuring message consistency, and synthesizing complex data for diverse audiences.",
      "interests": "Novel treatment mechanisms, clinical trial results, storytelling with data, effective slide deck preparation, compliance in medical communications.",
      "highlights": {
        "gi-cancer-asco-2024-practice-changing": [
          {
            "p": "<strong>S-EPEC Study Communications</strong>: As Manager of Medical Scientific Communications, the S-EPEC study comparing treatment approaches in esophageal adenocarcinoma offers rich content for scientific messaging. The study's focus on real-world treatment patterns between academic and community settings provides valuable material for developing clear, regulatory-aligned content and publication planning.",
            "start_time": 44.64
          },
          {
            "p": "<strong>Study Design Communication</strong>: The ARMANI study's complex patient selection criteria and endpoint design present opportunities for clear scientific narrative development. This framework helps translate trial methodology into accessible educational content.",
            "start_time": 298.26
          },
          {
            "p": "<strong>Treatment Evolution Messaging</strong>: The TRANSMET trial's insights on treatment sequencing require precise scientific communication. This data provides foundation for developing clear messaging about evolving treatment approaches.",
            "start_time": 350.94
          },
          {
            "p": "<strong>Combination Strategy Narrative</strong>: The Collision trial's exploration of novel combinations offers rich material for scientific storytelling. These findings support development of compelling narratives about advancing treatment paradigms.",
            "start_time": 401.94
          },
          {
            "p": "<strong>Endpoint Innovation Communication</strong>: The COMMIT study's novel endpoints present opportunities for innovative data visualization. This approach enhances communication of complex trial outcomes to diverse audiences.",
            "start_time": 455.74
          },
          {
            "p": "<strong>Clinical Implementation Messaging</strong>: The analysis of treatment patterns across different settings provides context for targeted communication strategies. This insight guides development of setting-specific educational materials.",
            "start_time": 500.68
          },
          {
            "p": "<strong>Outcomes Data Translation</strong>: The focus on patient-centered outcomes offers opportunities for impactful data presentation. This approach supports creation of clear benefit-risk communication materials.",
            "start_time": 546.28
          },
          {
            "p": "<strong>Protocol Communication Strategy</strong>: The studies' methodological innovations require clear scientific explanation. This context guides development of comprehensive educational resources about trial design.",
            "start_time": 594.18
          },
          {
            "p": "<strong>Collaborative Research Narrative</strong>: The emphasis on cross-disciplinary approaches provides material for team-based care messaging. This insight supports development of integrated communication strategies.",
            "start_time": 634.1
          }
        ],
        "asco-2024-and-esmo-gi-2024": [
          {
            "p": "<strong>Scientific Narrative Framework</strong>: Dr. Kuttner's structured presentation of complex oncology updates demonstrates effective scientific communication. His approach to integrating research updates with clinical context provides a valuable model for developing clear, impactful scientific narratives.",
            "start_time": 103.44
          },
          {
            "p": "<strong>Data Communication Strategy</strong>: The presentation's effective delivery of key statistics - 30,000 new US cases and global mortality rankings - showcases how to translate epidemiological data into compelling narratives that resonate with both clinical and non-clinical audiences.",
            "start_time": 225.52
          },
          {
            "p": "<strong>Clinical Context Development</strong>: The discussion of asymptomatic early-stage challenges provides crucial context for communications about diagnostic approaches. This narrative framework helps articulate the importance of early detection initiatives to various stakeholders.",
            "start_time": 296.96
          },
          {
            "p": "<strong>Research Impact Messaging</strong>: The Foundation's achievement of $1.45 million in research grants demonstrates effective research communication. This success story provides a template for communicating research progress and funding impact to diverse audiences.",
            "start_time": 378.76
          },
          {
            "p": "<strong>Scientific Innovation Narrative</strong>: Dr. Kuttner's explanation of cancer genomics and targeted therapies illustrates effective communication of complex scientific concepts. His approach to discussing biomarkers and immune-mediated therapies provides a model for translating advanced research into accessible content.",
            "start_time": 432.18
          },
          {
            "p": "<strong>Clinical Research Communication</strong>: The presentation's coverage of multi-institutional research initiatives demonstrates effective ways to communicate collaborative scientific efforts. This framework helps in developing comprehensive narratives about ongoing research programs.",
            "start_time": 488.94
          },
          {
            "p": "<strong>Guidelines Communication Strategy</strong>: The discussion of NCCN Guidelines provides insights for communicating treatment protocols effectively. This approach helps in developing clear, actionable content about clinical practice updates and implementation strategies.",
            "start_time": 544.18
          },
          {
            "p": "<strong>Patient Education Framework</strong>: The webinar's approach to patient education and advocacy demonstrates effective health communication strategies. This model supports the development of patient-centric content that bridges scientific complexity with accessibility.",
            "start_time": 594.66
          }
        ],
        "ucsf-bay-area-breast-cancer": [
          {
            "p": "<strong>Scientific Meeting Communication</strong>: The presentation's introduction of ASCO's role in breast cancer advances demonstrates effective scientific context-setting. This approach provides a model for communicating the significance of major oncology meetings and research milestones.",
            "start_time": 54.02
          },
          {
            "p": "<strong>Research Impact Narrative</strong>: The discussion of how conference presentations influence treatment approaches and study design shows effective research communication. This framework helps develop compelling narratives about the evolution of clinical practice.",
            "start_time": 115.3
          },
          {
            "p": "<strong>Expert Panel Communication</strong>: The introduction of multidisciplinary team members and their expertise demonstrates effective presenter credentialing. This approach enhances the authority and credibility of scientific communications.",
            "start_time": 174.1
          },
          {
            "p": "<strong>Digital Engagement Strategy</strong>: The webinar's implementation of Q&A functionality shows effective audience interaction management. This model informs the development of engaging virtual scientific communication formats.",
            "start_time": 218.66
          },
          {
            "p": "<strong>Clinical Research Narrative</strong>: The presentation of UCSF's endocrine optimization program demonstrates clear communication of complex trial designs. This approach guides the development of accessible research program communications.",
            "start_time": 296.38
          },
          {
            "p": "<strong>Innovation Communication</strong>: The discussion of telemedicine research shows effective translation of novel healthcare delivery concepts. This framework helps communicate emerging trends and their impact on patient care.",
            "start_time": 348.1
          },
          {
            "p": "<strong>Technical Content Translation</strong>: The explanation of axillary lymph node staging demonstrates effective communication of complex surgical concepts. This approach informs the development of clear, accessible technical content.",
            "start_time": 401.84
          },
          {
            "p": "<strong>Educational Content Strategy</strong>: The speaker's use of analogies and clear explanations shows effective knowledge translation. This model supports the development of engaging educational materials for various audiences.",
            "start_time": 452.1
          }
        ]
      }
    },
    "mia-chen": {
      "img": "img/mia-chen.jpg",
      "name": "Mia Chen",
      "role": "Director, Competitive Intelligence",
      "age": 42,
      "background": "Biostatistics and data analytics, 17 years in the pharmaceutical industry.",
      "specialties": "Competitor analysis, strategic planning, and market forecasting.",
      "clientele": "Executive leadership and business development teams.",
      "goals": "Provide actionable insights to anticipate competitive moves and inform strategic decisions.",
      "challenges": "Sifting through large datasets, aligning with evolving regulatory landscapes, and predicting market trends.",
      "interests": "Pipeline updates, ASCO/ESMO GI conference findings, emerging therapeutic areas, treatment paradigms, regulatory milestones, and innovation trends.",
      "highlights": {
        "gi-cancer-asco-2024-practice-changing": [
          {
            "p": "<strong>S-EPEC Study Competitive Analysis</strong>: For your role as Director of Competitive Intelligence, the S-EPEC study's findings on treatment patterns between academic and community settings provide crucial competitive insights. This data helps anticipate market shifts and informs strategic decisions about positioning in the esophageal adenocarcinoma treatment landscape.",
            "start_time": 44.64
          },
          {
            "p": "<strong>Trial Design Intelligence</strong>: The ARMANI study's innovative approach reveals emerging trends in clinical development strategy. This insight helps track competitor trial designs and identify potential shifts in development approaches.",
            "start_time": 298.26
          },
          {
            "p": "<strong>Treatment Landscape Analysis</strong>: The TRANSMET trial's sequencing strategy indicates evolving competitive dynamics. This data informs understanding of market positioning and potential therapeutic competition.",
            "start_time": 350.94
          },
          {
            "p": "<strong>Competitive Strategy Assessment</strong>: The Collision trial's combination approach signals strategic directions in product development. This insight helps anticipate competitor moves and identify partnership opportunities.",
            "start_time": 401.94
          },
          {
            "p": "<strong>Innovation Trajectory Analysis</strong>: The COMMIT study's novel endpoints demonstrate emerging evaluation frameworks. This approach reveals competitive advantages and potential market differentiation strategies.",
            "start_time": 455.74
          },
          {
            "p": "<strong>Market Segmentation Insights</strong>: The analysis of academic versus community treatment patterns reveals market dynamics. This understanding guides competitive positioning across different practice settings.",
            "start_time": 500.68
          },
          {
            "p": "<strong>Value Proposition Analysis</strong>: The focus on patient-centered outcomes indicates evolving value metrics. This insight helps assess competitive positioning and market access strategies.",
            "start_time": 546.28
          },
          {
            "p": "<strong>Development Pipeline Assessment</strong>: The studies' methodological approaches reveal R&D strategy trends. This knowledge supports competitive pipeline analysis and development forecasting.",
            "start_time": 594.18
          },
          {
            "p": "<strong>Stakeholder Strategy Mapping</strong>: The emphasis on cross-disciplinary collaboration shows engagement trends. This insight guides understanding of competitor influence strategies and partnership approaches.",
            "start_time": 634.1
          }
        ],
        "asco-2024-and-esmo-gi-2024": [
          {
            "p": "<strong>Research Institution Landscape</strong>: Dr. Kuttner's affiliation with MGH and Harvard Medical School, along with leadership roles in NRG and NCI committees, reveals the competitive dynamics of institutional research. This network analysis helps identify key research centers and potential collaboration opportunities.",
            "start_time": 103.44
          },
          {
            "p": "<strong>Market Size Analysis</strong>: The presentation's data on 30,000 annual US diagnoses and global mortality rankings provides crucial market sizing insights. This epidemiological context helps assess market potential and identify regional opportunities for strategic focus.",
            "start_time": 225.52
          },
          {
            "p": "<strong>Disease Burden Analysis</strong>: The discussion of early-stage diagnostic challenges highlights an important market gap. Understanding these clinical limitations informs competitive positioning in the diagnostic and early detection market segments.",
            "start_time": 296.96
          },
          {
            "p": "<strong>Research Funding Analysis</strong>: The Foundation's success in securing $1.45 million in research grants indicates growing investment in gastric cancer research. This funding pattern analysis helps track research priorities and potential market directions.",
            "start_time": 378.76
          },
          {
            "p": "<strong>Technology Innovation Mapping</strong>: Dr. Kuttner's focus on cancer genomics, targeted therapies, and immune-mediated approaches provides insights into emerging technology trends. This information is vital for mapping competitive landscapes in precision medicine.",
            "start_time": 432.18
          },
          {
            "p": "<strong>Research Partnership Analysis</strong>: The presentation's coverage of multi-institutional collaborations, including Stand Up to Cancer and NCI support, reveals key strategic alliances. This network analysis helps identify influential research partnerships and funding patterns.",
            "start_time": 488.94
          },
          {
            "p": "<strong>Treatment Protocol Evolution</strong>: The discussion of NCCN Guidelines development provides insights into evolving treatment standards. This understanding is crucial for anticipating market changes and competitive positioning in therapeutic areas.",
            "start_time": 544.18
          },
          {
            "p": "<strong>Stakeholder Landscape Assessment</strong>: The webinar's emphasis on patient advocacy and education demonstrates the growing influence of patient organizations. This stakeholder analysis informs engagement strategies and market access approaches.",
            "start_time": 594.66
          }
        ],
        "ucsf-bay-area-breast-cancer": [
          {
            "p": "<strong>Conference Strategy Analysis</strong>: The discussion of ASCO's role in presenting breakthrough research reveals key scientific platform dynamics. Understanding conference positioning helps identify strategic opportunities for data presentation and competitive differentiation.",
            "start_time": 54.02
          },
          {
            "p": "<strong>Research Impact Assessment</strong>: The analysis of how conference presentations influence treatment approaches provides valuable competitive context. This insight helps evaluate the market impact of new clinical data and research initiatives.",
            "start_time": 115.3
          },
          {
            "p": "<strong>Institution Capability Analysis</strong>: UCSF's multidisciplinary approach, featuring surgical, medical oncology, and fellowship programs, demonstrates institutional strengths. This framework helps assess competitive positioning in the academic research landscape.",
            "start_time": 174.1
          },
          {
            "p": "<strong>Digital Platform Strategy</strong>: The webinar's implementation of interactive Q&A reveals evolving engagement models. This insight informs competitive analysis of digital scientific communication platforms and virtual conference strategies.",
            "start_time": 218.66
          },
          {
            "p": "<strong>Research Program Evaluation</strong>: The presentation of UCSF's endocrine optimization program reveals strategic research priorities. This information helps assess institutional focus areas and potential competitive advantages in clinical research.",
            "start_time": 296.38
          },
          {
            "p": "<strong>Healthcare Innovation Analysis</strong>: The discussion of telemedicine research, supported by ASCO and AACR, highlights emerging care delivery trends. This insight helps evaluate competitive positioning in digital health innovation.",
            "start_time": 348.1
          },
          {
            "p": "<strong>Technical Innovation Assessment</strong>: The detailed explanation of axillary lymph node staging approaches reveals surgical technique evolution. This information helps analyze competitive differentiation in surgical innovation and technology adoption.",
            "start_time": 401.84
          },
          {
            "p": "<strong>Educational Strategy Analysis</strong>: The speaker's approach to explaining complex concepts demonstrates effective knowledge translation. This model helps evaluate competitive positioning in medical education and professional development.",
            "start_time": 452.1
          }
        ]
      }
    }
  },
  "prompts": {
    "interests": "Given this information about a financial advisor, return a JSON object {\"interests\": \"...\"} containing comma-separated keywords they would be interested in when listening to a financial podcast.",
    "highlights": "Given this video transcript:\n\nTitle: ${title}\n${transcript_with_timing}\n\nWrite a few paragraphs for:\n\n${profile}\n\nExplain the implications for their investors and how they can leverage this information to maximize returns for their clients. Respond as JSON paragraphs with timing.\n\n```json\n[\n{\"p\": \"[firstname], this video can help your [clientele] about ...\",\"start_time\": ...},{\"p\": \"[insight 1]\",\"start_time\": ...},{\"p\": \"[insight 2]\",\"start_time\": ...},{\"p\": \"[insight 3]\",\"start_time\": ...},]"
  }
}
